<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Spectrum and frequencies of extraocular features reported in CEP290-associated ciliopathy</dc:title><dc:creator>Vrabič,	Nika	(Avtor)
	</dc:creator><dc:creator>Fakin,	Ana	(Avtor)
	</dc:creator><dc:creator>Tekavčič Pompe,	Manca	(Avtor)
	</dc:creator><dc:subject>Leber's congenital amaurosis</dc:subject><dc:subject>phenotype-genotype correlation</dc:subject><dc:subject>Senior-Loken syndrome</dc:subject><dc:subject>Joubert syndrome</dc:subject><dc:subject>CEP290</dc:subject><dc:subject>ciliopathy</dc:subject><dc:description>Pathogenic variants in the CEP290 gene may result in a broad spectrum of diseases, ranging from lethal neonatal syndromes to isolated retinopathy. A detailed review of the clinical spectrum with the incidence of affected extraocular systems has not yet been published. A review of published papers was carried out to provide a comprehensive report on systemic signs and symptoms associated with CEP290 ciliopathies and to explore the genotype-phenotype correlation. Genetic and clinical data were collected on patients with biallelic variants in the CEP290 gene and the extraocular tissues affected. Genotype-phenotype analysis was performed. Two hundred thirty-five patients were included in the analysis. The most frequently reported organs affected, after the eye, were the central nervous system (82.6%, 194/235), followed by the kidney (53.2%, 125/235), skeletal system (15.3% 36/235), and a large spectrum of other, less frequently reported clinical manifestations. Patients with two variants that together predictably resulted in a low amount of CEP290 protein showed a significant association with having two or more extraocular organ systems affected. This is the most extensive report to date on patients with CEP290-ciliopathy and affected extraocular tissues. Based on these findings and previous publications, systemic screening is proposed, together with a clinical pathway for patients with CEP290-related ciliopathy.</dc:description><dc:date>2024</dc:date><dc:date>2024-09-13 09:51:40</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>161731</dc:identifier><dc:identifier>UDK: 617.7</dc:identifier><dc:identifier>ISSN pri članku: 1773-0597</dc:identifier><dc:identifier>DOI: 10.1016/j.jfo.2024.104232</dc:identifier><dc:identifier>COBISS_ID: 207372803</dc:identifier><dc:language>sl</dc:language></metadata>
